A new avenue for targeted drug delivery has been proposed by researchers from The Grainger College of Engineering at the ...

One of the longstanding challenges in chemical biology has been finding ways to directly observe biological processes at work ...

Biotechnology is often hailed as the future of cosmetic formulations. Here,, Director and Cosmetic Chemist at the Institute ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology ... non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment ...

Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment -- TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) ...

TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company ... The Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial ...

The life science group Sartorius launches the new Octet® R8e biolayer interferometry (BLI) system, providing researchers with ...

About THIO-101, a Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase ... the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy ...